Medipharm Labs Delays Q1 Financials, Announces Inventory Impairments

Medipharm Labs (TSX: LABS) this morning announced that it will be delaying its first quarter financial results, with the company giving a blanket statement that it expects to file by the end of June. Furthermore, the company also announced that it will be conducting impairments on inventory among other items as a result of the ongoing pandemic.

With respect to inventory, Medipharm this morning let it be known that the company is expecting to impair anywhere from $10 to $15 million within its first quarter financials. The company blamed the impairment on reduced demand due to the current coronavirus pandemic. Overall, a number of reasons were cited that lead up to the announcement within the news release including:

  • Reduced staff at provincial distributors and private retailers, which the company claims resulted in reduced purchase orders and delivery availability, impacting white label sales.
  • Delays in anticipated expansions of retail channels and slower licensing of cannabis derivative businesses.
  • Producers being slower to implement capabilities to convert bulk extract to finished goods due to operational slowdowns.

These factors were all blamed for oversupply conditions of bulk extract product within the Canadian market, including subsequent lower selling price points and volumes, which ultimately resulted in these writedowns occurring. The company provided no guidance on revenue figures.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

Medipharm Labs reported product inventories of $51.5 million as of December 31, 2019. The company last traded at $1.54 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Medipharm Labs Sells Off Australian Assets

MediPharm Labs (TSX: LABS) appears to be slowly pulling back on its international endeavours. The...

Monday, July 11, 2022, 08:11:52 AM

Medipharm Labs CFO Resigns From Company For Family Reasons

Medipharm Labs (TSX: LABS) this morning announced changes to their leadership team within a brief...

Thursday, November 12, 2020, 07:41:36 AM

Medipharm Labs To Raise $20 Million Via Bought Deal Financing

Medipharm Labs (TSX: LABS) this evening announced that it will be conducting a bought deal...

Monday, March 1, 2021, 04:57:27 PM

Medipharm Labs Ships First Topical Products

Medipharm Labs (TSX: LABS) is now in the cannabis topicals business. The company announced this...

Wednesday, March 25, 2020, 08:20:53 AM

Medipharm Labs Increases Bought Deal To $29.0 Million

Medipharm Labs (TSX: LABS) has increased the size of the bought deal financing announced last...

Tuesday, March 2, 2021, 09:26:39 AM